Boston posts May Taxus stent sales:
This article was originally published in Clinica
Boston Scientific claims it still holds more than 70% of the US drug-eluting stent market after reporting revenues from its Taxus Express2 stent of $157m in the US and $201m worldwide for 20 selling days in May. The paclitaxel-coated coronary stent was launched in early March this year following FDA approval and has significantly boosted first-quarter results for the Natick, Masachusettes-based company (see Clinica No 1104, p20). April sales figures for the Taxus system were $163m in the US and $205m worldwide. The company estimates that approximately 75% of total stent placements now involve drug-eluting stents.